Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Value-Added Medicines

Set Alert for Value-Added Medicines

Accord Agrees Leuprolide Deal as Part of Differentiation Strategy

Accord is furthering its push into added-value medicines by entering into a licensing agreement for Foresee’s injectable suspension leuprolide injectable.
Value-Added Medicines Deals

Celltrion’s Subcutaneous Infliximab Shows Promise

Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.

Biosimilars Strategy

TLC Seeks A Second Opinion On Doxolipad

After the CHMP last month refused to recommend granting approval for TLC’s doxorubicin hybrid, the firm has asked the committee within the EMA to revisit its opinion.

Europe Regulation

Two New Categories Join GGB Awards In 2019

Two new categories – Value Added Medicine Of The Year and Legal Strategy Of The Year – have been added to the Global Generics & Biosimilars Awards in 2019, which will take place on 5 November in Frankfurt, Germany.

Generic Drugs Biosimilars

European Studies Help Plan A Path Forward For Value Added Medicines

Six value added medicines case studies across six European countries are featured in the latest IQVIA report for Medicines for Europe. Each of them, according to the association’s sector chair Arun Narayan, helps point to a way forward for value added medicines in Europe.

Europe Value-Added Medicines

Pfenex One Step Closer To Teriparatide As FDA Accepts NDA

Pfenex maintains it can introduce a follow-on version of Eli Lilly’s Forteo in the fourth quarter of this year, after receiving a target goal date of 7 October 2019 from the FDA.

Value-Added Medicines FDA
See All